Novel Immunotherapy Combos Target GITR to Step on the Gas

Jane De Lartigue, PhD
Published: Monday, Oct 21, 2019
Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.1 In particular, immune checkpoint inhibitors (ICIs), which block signals that dampen T-cell activity, are a major breakthrough, yielding the possibility of long-term clinical benefit across a growing number of tumor types.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication